# Optimizing Haploidentical Aplastic Anemia Transplantation (BMT CTN 1502)

> **NCT02918292** · PHASE2 · COMPLETED · sponsor: **Medical College of Wisconsin** · enrollment: 32 (actual)

## Conditions studied

- Severe Aplastic Anemia

## Interventions

- **DRUG:** Antithymocyte Globulin (ATG)
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide
- **RADIATION:** Total Body Irradiation (TBI)
- **PROCEDURE:** Haplo HSCT
- **DRUG:** Tacrolimus
- **DRUG:** Mycophenolate mofetil (MMF)
- **DRUG:** G-CSF

## Key facts

- **NCT ID:** NCT02918292
- **Lead sponsor:** Medical College of Wisconsin
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-03
- **Primary completion:** 2021-08-17
- **Final completion:** 2021-08-17
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2026-03-31

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02918292

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02918292, "Optimizing Haploidentical Aplastic Anemia Transplantation (BMT CTN 1502)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT02918292. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*